Renon 10mg Tablet 10pcs

Uses of Renon 10mg Tablet

• Treatment of Chronic kidney disease

How does Renon 10mg Tablet work?

 Renon 10 blocks and prevents this receptor from overactivation, which can damage different parts of the body such as the kidneys, heart, and blood vessels.

Common Side Effects of Finerenone:

1. High Potassium Level (Hyperkalemia):
   • Signs: Weakness, tiredness, nausea, numbness in hands and lips, muscle cramps, slow pulse rate.
2. Low Sodium Level (Hyponatremia):
   • Signs: Nausea, tiredness, headache, confusion, muscle cramps.
3. High Uric Acid Level (Hyperuricemia):
   • Symptoms may not always be obvious, but high levels can lead to conditions like gout.
4. Low Blood Pressure (Hypotension):
   • Signs: Dizziness, fainting.
5. Low Hemoglobin (Hb) Levels:
   • Symptoms might include fatigue, weakness, pallor, and shortness of breath.

Monitoring and Management:

• Frequent checks of potassium, sodium, and uric acid levels are recommended to manage and mitigate side effects.
• Report any signs or symptoms promptly, especially if you experience severe symptoms related to potassium, sodium, or blood pressure changes.

Your healthcare provider will guide you on how to handle these side effects and adjust your treatment if necessary.

Quick Suggestions:

• For patients who cannot swallow whole tablets, Renon 10 may be crushed and mixed with water or soft foods, before taking it.
• Inform your doctor if you are taking potassium supplements or any other medications for high blood pressure or heart disease.
• Women of childbearing potential should use effective contraception during the treatment to avoid getting pregnant.
• Renon 10 contains lactose; inform your doctor if you have lactose intolerance.
• Lactating women should exercise caution while on treatment with this medicine.

Indication of Renon 10mg Tablet

Management of chronic kidney disease associated with type 2 diabetes in adults

Pharmacology of Finerenone:

• Mechanism of Action: Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR). It blocks MR-mediated sodium reabsorption and MR overactivation in both epithelial (e.g., kidneys) and nonepithelial tissues (e.g., heart, blood vessels). This helps prevent fibrosis and inflammation.
• Potency and Selectivity: Finerenone is highly potent and selective for MR, with no significant affinity for androgen, progesterone, estrogen, or glucocorticoid receptors.
• Effects on Blood Pressure: In clinical studies, finerenone reduced mean systolic blood pressure by 3 mmHg and diastolic blood pressure by 1-2 mmHg within the first month of treatment. This reduction remained stable thereafter.
• QT Interval: Finerenone does not prolong the QT interval at doses up to 4 times the maximum recommended dose.
• Absorption: Finerenone is fully absorbed after oral administration, with a bioavailability of 44%. Peak plasma concentration (Cmax) is reached between 0.5 and 1.25 hours post-dosing. Food does not significantly affect its absorption.
• Distribution: The volume of distribution at steady-state is 52.6 L, with 92% plasma protein binding, primarily to serum albumin.
• Elimination: The terminal half-life is about 2-3 hours, and the systemic clearance is 25 L/h.
• Metabolism: Finerenone is primarily metabolized by CYP3A4 (90%) and to a lesser extent by CYP2C8 (10%) to inactive metabolites. About 80% of the dose is excreted in urine.

Dosage and Administration of Finerenone:

Starting Dosage:

• eGFR ≥60 mL/min/1.73 m²: Start with 20 mg once daily.
• eGFR ≥25 to <60 mL/min/1.73 m²: Start with 10 mg once daily.
• eGFR <25 mL/min/1.73 m²: Not recommended.

Dose Adjustment:

• Increase the target dose of 20 mg once daily after 4 weeks, based on eGFR and serum potassium levels.
• Tablets can be taken with or without food.
• For patients unable to swallow whole tablets, they can be crushed and mixed with water or soft foods.

Monitoring:

• Measure serum potassium 4 weeks after initiating treatment and adjust the dose as needed.
• If serum potassium levels are between 4.8 and 5.0 mEq/L, consider starting treatment with additional monitoring.
• Continue monitoring serum potassium 4 weeks after dose adjustments and throughout the treatment course.

Interactions with Renon (Finerenone):

Renon 10mg Tablet can interact with various medications, potentially affecting its efficacy or increasing the risk of adverse effects. Here are key interactions to be aware of:

Medicines That May Affect Renon 10mg Tablet:

Antifungal Agents:

• Itraconazole
• Ketoconazole
• These medications can inhibit CYP3A4, a key enzyme involved in the metabolism of Finerenone, potentially increasing its levels and risk of side effects.

Anti-HIV Agents:

• Ritonavir
• Nelfinavir
• Cobicistat
• These drugs can also inhibit CYP3A4, affecting Finerenone metabolism.

Antibacterial Agents:

• Clarithromycin
• Telithromycin
• These may inhibit CYP3A4 and impact Finerenone levels.

Diuretics:

• Amiloride
• Triamterene
• These can increase potassium levels, compounding the risk of hyperkalemia with Finerenone.

Potassium Supplements:

• Can increase potassium levels, adding to the risk of hyperkalemia.

Other Mineralocorticoid Receptor Antagonists:

• Eplerenone
• Esaxerenone
• Spironolactone
• Canrenone
• Like Finerenone, these can increase potassium levels and may have additive effects.

Trimethoprim and Combination Products:

• Trimethoprim
• Trimethoprim + Sulfamethoxazole
• These can elevate potassium levels, increasing the risk of hyperkalemia.

Antiepileptic Medicines:

• Carbamazepine
• Phenytoin
• Phenobarbital
• These may induce CYP3A4, potentially decreasing Finerenone levels.

Antidepressants:

• St. John's Wort
• Fluvoxamine
• Nefazodone
• These can affect CYP3A4 activity, altering Finerenone metabolism.

Blood Pressure-Lowering Agents:

• Atenolol
• Amlodipine
• Enalapril
• Telmisartan
• Olmesartan
• These may interact with Finerenone, potentially affecting blood pressure and potassium levels.

Other Agents:

• Erythromycin
• Verapamil
• Rifampicin
• Rifampicin may induce CYP3A4, reducing Finerenone efficacy.

Contraindications for Finerenone:

1. Allergy: Hypersensitivity to finerenone or any of its ingredients.
2. Strong CYP3A4 Inhibitors: Concomitant use with strong CYP3A4 inhibitors, such as:
   • Itraconazole
   • Ketoconazole
   • Ritonavir
   • Nelfinavir
   • Cobicistat
   • Clarithromycin
   • Telithromycin
   • Nefazodone
3. Addison's Disease: Addison's disease (a condition where the adrenal glands do not produce enough hormones).

Pregnancy & Lactation

Precautions & Warnings

• Always inform your healthcare provider about all medications, supplements, or herbal products you are taking.
• Regular potassium levels and kidney function monitoring are crucial when using Finerenone, especially if any interacting medications are involved.

Storage:

Store below 30°C, away from light and moisture. Keep out of reach of children.